Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
